𝔖 Bobbio Scriptorium
✦   LIBER   ✦

HCV core antigen and combination (antigen/antibody) assays for the detection of early seroconversion

✍ Scribed by George J. Dawson


Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
84 KB
Volume
79
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis


Detection of antibodies against hepatitis C virus (HCV) and/or detection of HCV RNA by nucleic acid testing (NAT) are the commonly utilized methods for detecting exposure to HCV in both blood screening and diagnostic laboratories. While several HCV core antigen tests have been developed over the last 10 years, these assays have not gained wide acceptance in routine laboratory practices, due in part to inadequate sensitivity. Over the last several years, improvements have been made in the formulation of the HCV core antigen assays that have resulted in significant sensitivity improvements. Recent studies indicate that between 85% and 98% of preseroconversion samples that are HCV RNA positive are detected with the improved HCV core antigen assays. These improved assays include stand-alone HCV core antigen tests and HCV antigen/antibody combination tests. As such, these assays could provide an alternative to HCV NAT in blood banks where such testing has not already been implemented, and may be utilized in diagnostic laboratories to identify early HCV infection. J. Med. Virol.


πŸ“œ SIMILAR VOLUMES


Incremental detection of HIV infections
✍ Philip Cunningham; Jean Downie; Peter O'Loughlin; Sara Evans; Jenette Black πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 98 KB

Detection of acute cases of human immunodeficiency virus (HIV) infection by the direct detection of HIV antigen or HIV nucleic acid assays is well known with an estimated 5-9 days reduction in the pre-seroconversion 'window period' by the detection of HIV specific antibodies. The aim of this study w

Evaluation of a total hepatitis C virus
✍ Pierpaolo Valcavi; Maria Cristina Medici; Francesca Casula; Maria Cristina Arcan πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 211 KB

## Abstract A new, sensitive enzyme immunoassay has been developed for detecting and quantifying total hepatitis C virus (HCV) core antigen in anti‐HCV positive or negative sera (β€œ__trak__‐__C__ℒ”, Ortho Clinical Diagnostics, Raritan, NJ). The purpose of this study was to evaluate the performance o

HCV core immunodominant region analysis
✍ Jolivet-Reynaud, Colette; Dalbon, Pascal; Viola, Florence; Yvon, StΓ©phane; Paran πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 143 KB πŸ‘ 2 views

Monoclonal antibodies (MAbs) were generated by immunizing mice with a truncated recombinant protein corresponding to the immunodominant region (residues 1-120) of hepatitis C virus (HCV) nucleocapsid protein. The specific recognition by either human sera or mouse monoclonal antibodies of overlapping

Total HCV core antigen assay: A new mark
✍ Alessandro R. Zanetti; Luisa RomanΓ²; Maurizia Brunetto; Massimo Colombo; Giorgio πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 192 KB

## Abstract The ability of the total hepatitis C virus (HCV) core antigen assay was evaluated for monitoring the therapeutic responses of HCV‐infected patients treated with interferon. The ability to detect and quantitate an independent structural protein component of HCV, in the presence of circul

Simultaneous detection of hepatitis C vi
✍ Alhusain J. Alzahrani πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 83 KB

## Abstract Drug users and particularly, injecting drug users, are at increased risk for infection with hepatitis C virus (HCV). The aims of the study were to simultaneously detect HCV core antigen and specific antibodies in sera from Saudi drug users using the new HCV combination assay and to comp

Selective detection of IgM-antibody agai
✍ Wolfram H. Gerlich; Wilfried LΓΌer πŸ“‚ Article πŸ“… 1979 πŸ› John Wiley and Sons 🌐 English βš– 701 KB

IgM antibody against core antigen of the hepatitis B virus (anti-HBc IgM) was selectively determined by a new enzyme immunoassay (EIA). Microtiter plates were coated with anti-human micro chain immunoglobulin. On addition of serum IgM is bound by a factor of about 4,000 more than IgG. After removing